Adjuvant therapy
Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial
PUBLICATION: European Journal of Cancer AUTHORS: Valesca P. Retel, Read More
Controlling Technical Variation Amongst 6693 Patient Microarrays of the Randomized MINDACT Trial
PUBLICATION: Communications Biology AUTHORS: Laurent Jacob, Anke Witteveen, Inรจs Beumer, Read More
ASCO 2020: 8q22 Poster
PUBLICATION: ASCO 20 AUTHORS: Sami Diab, Matei P. Socoteanu, Carlos Read More
SABCS 2019: Cyclin E Expression
AUTHORS: Lorenza Mittempergher, Joseph McKelley, Rajith Bhaskaran, Sahra Uygun, Reneฬ Read More
SABCS 2019: PROMIS Clinical Risk
AUTHORS: Michaela Tsai, Hatem Soliman, Shelly Lo, Rubina Qamar, Raye Read More
Prospective Validation of a Genomic Assay in Breast Cancer: The 70-Gene MammaPrint Assay and the MINDACT Trial
PUBLICATION: Acta Medica Academica. Volume 48 (2) August 2019 AUTHOR: Read More
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline GalleryRole of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline
PUBLICATION: Journal of Clinical Oncology 37, no. 22 (August 01, Read More
The Changing Role of Gene-Expression Profiling in the Era of Deescalating Adjuvant Chemotherapy in Early-Stage Breast Cancer
PUBLICATION: Ann Surg Oncol (2019) 26: 3495. https://doi.org/10.1245/s10434-019-07511-8. AUTHORS: J.E.C. Read More
Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study
PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x. AUTHORS: Read More
Association of 70-Gene Signature Assay Findings With Physiciansโ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay GalleryAssociation of 70-Gene Signature Assay Findings With Physiciansโ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
Association of 70-Gene Signature Assay Findings With Physiciansโ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
PUBLICATION: JAMA Oncol. 2018; 4(1):e173470. doi:10.1001/jamaoncol.2017.3470. AUTHORS: Michaela Tsai, MD; Read More
